Clinuvel Pharmaceuticals Ltd | WebDisclosure

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Clinuvel Pharmaceuticals Ltd

Home
Companies
Clinuvel Pharmaceuticals Ltd

BRIEF

published on 09/30/2025 at 10:57, 2 months 4 days ago

CLINUVEL Pharmaceuticals Strengthens Position with Strategic Moves

Capital Markets Biotech Growth NASDAQ Uplisting CLINUVEL Pharmaceuticals Trade Tariffs
BRIEF

published on 09/30/2025 at 10:57, 2 months 4 days ago

CLINUVEL Pharmaceuticals renforce sa position grâce à des opérations stratégiques

Marchés Des Capitaux Croissance De La Biotechnologie Cotation En Hausse Au NASDAQ CLINUVEL Pharmaceuticals Tarifs Commerciaux
PRESS RELEASE

published on 09/30/2025 at 10:52, 2 months 4 days ago

Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy
CLINUVEL strengthens global position with tariff advantage and Nasdaq uplisting. Strategic decisions by CLINUVEL highlighted in research note by Parmantier & Cie. GmbH

Global Growth Strategy Parmantier & Cie. GmbH NASDAQ Uplisting CLINUVEL Pharmaceuticals Tariff Advantage
BRIEF

published on 06/23/2025 at 12:46, 5 months 11 days ago

CLINUVEL Pharmaceuticals: Positive Outlook Amid Strategic Developments

Investment Recommendation North America Expansion SCENESSE® CLINUVEL Pharmaceuticals Vitiligo Treatment
BRIEF

published on 06/23/2025 at 12:46, 5 months 11 days ago

CLINUVEL Pharmaceuticals : Perspectives positives dans un contexte de développements stratégiques

Recommandation D'investissement Expansion En Amérique Du Nord SCENESSE® CLINUVEL Pharmaceuticals Traitement Du Vitiligo
PRESS RELEASE

published on 06/23/2025 at 12:41, 5 months 11 days ago

Original-Research: CLINUVEL Pharmaceuticals (von Parmantier & Cie. GmbH): Buy
Research update by Parmantier & Cie. GmbH on CLINUVEL Pharmaceuticals, highlighting CEO's return and business model enhancement with SCENESSE® for vitiligo in North America. Strategic growth opportunities discussed

Research Update Strategic Growth CLINUVEL Pharmaceuticals CEO Return SCENESSE For Vitiligo
BRIEF

published on 03/07/2025 at 16:26, 8 months 28 days ago

CLINUVEL Pharmaceuticals Sees Record Growth in H1/FY25

Investment Strategy Market Expansion Record Growth CLINUVEL Pharmaceuticals Clinical Projects
BRIEF

published on 03/07/2025 at 16:26, 8 months 28 days ago

CLINUVEL Pharmaceuticals enregistre une croissance record au premier semestre de l'exercice 2025

Stratégie D'investissement Croissance Record Expansion Du Marché Produits Pharmaceutiques CLINUVEL Projets Cliniques
PRESS RELEASE

published on 03/07/2025 at 16:21, 8 months 28 days ago

Original-Research: CLINUVEL Pharmaceuticals (von Parmantier & Cie. GmbH): BUY
CLINUVEL Pharmaceuticals demonstrates impressive H1/FY25 results, increasing revenue and EPS. New strategy focuses on vitiligo treatment, leading in science-based cosmetic products

Investment Recommendation CLINUVEL Pharmaceuticals H1/FY25 Results Vitiligo Treatment Cosmetic Products

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 6 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 11 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 41 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 36 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 41 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 11 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 50 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 16 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 26 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 31 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:14, 12 hours 26 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 41 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 41 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 56 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 56 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE